Table 2.

In vitro GI % for compounds (8a–c, 9 and 10a, c, d), at 10 μM concentration, towards the subpanel cancer cell lines

	Compounda
Subpanel / Cell line	8a	8b	8c	9	10a	10c	10d
Leukaemia
CCRF-CEM	101	52	–	–	–	17	–
HL-60(TB)	123	12	10	18	22	–	–
K-562	83	33	18	–	30	20	–
MOLT-4	110	50	–	13	35	19	14
RPMI-8226	125	30	–	–	13	–	–
SR	89	–	19	11	50	58	33
Non-Small Cell Lung Cancer
A549/ATCC	36	28	13	–	–	–	–
EKVX	50	40	–	38	–	15	33
HOP-62	25	21	–	–	–	–	–
HOP-92	63	–	11	14	–	–	–
NCI-H226	116	–	–	16	13	56	41
NCI-H23	52	12	–	–	12	–	–
NCI-H322M	53	–	–	–	–	–	–
NCI-H460	68	11	19	–	–	–	–
NCI-H522	86	19	–	10	31	34	17
Colon cancer
COLO 205	116	–	–	–	30	–	–
HCC-2998	53	–	–	–	–	–	–
HCT-116	60	21	20	–	24	28	–
HCT-15	77	23	–	–	15	22	10
HT29	83	25	–	–	10	–	–
KM12	40	–	11	–	–	–	–
SW-620	64	–	–	–	–	–	–
CNS cancer
SF-268	54	–	–	–	–	–	–
SF-295	29	–	–	–	–	–	–
SF-539	66	–	10	–	–	–	–
SNB-19	37	–	22	–	–	–	–
SNB-75	15	–	–	33	18	–	–
U251	60	13.32	28	–	10	–	–
Melanoma
LOX IMVI	69	–	–	–	–	–	–
MALME-3M	49	–	–	–	26	–	–
M14	44	–	–	–	12	–	–
MDA-MB-435	127	–	–	–	–	–	–
SK-MEL-2	65	–	–	–	–	–	–
SK-MEL-28	41	–	–	–	–	–	–
SK-MEL-5	51	–	–	–	–	–	–
UACC-257	41	–	–	–	–	–	–
UACC-62	60	11	–	–	25	15	19
Ovarian cancer
IGROV1	61	–	–	–	28	31	23
OVCAR-3	98	–	–	–	21	13	–
OVCAR-4	58	–	–	–	27	22	–
OVCAR-5	16	–	–	–	–	–	–
OVCAR-8	53	15	29	–	15	11	–
NCI/ADR-RES	24	15	–	–	–	–	–
SK-OV-3	12	–	–	–	–	–	–
Renal cancer
786-0	36	–	–	–	–	–	–
A498	43	–	–	–	–	–	–
ACHN	45	15	–	–	–	11	–
RXF 393	89	–	–	–	11	–	–
SN12C	51	–	–	–	–	–	–
TK-10	–	–	–	–	–	–	–
UO-31	40	19	–	14	33	29	23
Prostate
PC-3	82	32	–	–	22	10	–
DU-145	34	13	–	–	–	–	–
MCF7	91	29	15	10	33	31	18
Breast cancer
MDA-MB-231	66	–	–	11	–	–	–
HS 578T	26	–	–	–	–	–	–
T-47D	61	35	–	13	56	50	30
MDA-MB-468	75	11	17	–	20	54	36
BT-549	37	–	–	–	–	–	–
Sensitive cell lines no.	58	26	14	12	27	20	12

^aOnly GI % higher than 10% are shown.